Seres Therapeutics (MCRB) News Today $16.69 -0.17 (-1.01%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$16.28 -0.41 (-2.46%) As of 04:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Seres Therapeutics’ Earnings Call: Progress Amid ChallengesAugust 16 at 12:06 AM | theglobeandmail.comSeres Therapeutics Reports Q2 Results and Leadership ChangeAugust 8, 2025 | theglobeandmail.comSeres (MCRB) Q2 Loss Narrows 34%August 6, 2025 | fool.comSeres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comSeres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 6, 2025 | globenewswire.comSeres Therapeutics (MCRB) Expected to Announce Earnings on WednesdayJuly 31, 2025 | marketbeat.comSeres Therapeutics: Speculative Gem Backed By SER‑155 FDA BreakthroughJuly 31, 2025 | seekingalpha.comSeres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025July 22, 2025 | globenewswire.comSBI Securities Co. Ltd. Purchases 48,013 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB)July 20, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Cross Above Fifty Day Moving Average - What's Next?July 5, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50-Day Moving Average - Here's What HappenedJune 5, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest UpdateJune 3, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Reduce" by BrokeragesMay 29, 2025 | marketbeat.comSeres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingMay 27, 2025 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average - Here's WhyMay 19, 2025 | marketbeat.comStockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to HoldMay 11, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.comMay 11, 2025 | marketbeat.comSeres Therapeutics' (MCRB) Neutral Rating Reaffirmed at Chardan CapitalMay 10, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comChardan Capital Downgrades Seres Therapeutics (MCRB)May 9, 2025 | msn.comSeres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comSeres Therapeutics reports Q1 EPS $3.75, consensus $1.97May 7, 2025 | msn.comSeres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comSeres Therapeutics Q1 2025 Earnings PreviewMay 6, 2025 | msn.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Hold" by BrokeragesMay 5, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50-Day Moving Average - Here's What HappenedMay 4, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.comMay 3, 2025 | marketbeat.comSeres Therapeutics (MCRB) Projected to Post Quarterly Earnings on WednesdayMay 2, 2025 | marketbeat.comSeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesApril 29, 2025 | globenewswire.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Decrease in Short InterestApril 28, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Hits New 12-Month Low - Here's What HappenedApril 25, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Up 10% - Still a Buy?April 24, 2025 | marketbeat.comPetri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock splitApril 24, 2025 | bizjournals.comSeres Therapeutics trading resumesApril 24, 2025 | markets.businessinsider.comSeres Therapeutics trading halted, volatility trading pauseApril 24, 2025 | markets.businessinsider.comSeres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025April 23, 2025 | globenewswire.comSeres Therapeutics trading halted, news pendingApril 22, 2025 | markets.businessinsider.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of "Hold" from BrokeragesApril 9, 2025 | marketbeat.comFY2025 Earnings Estimate for MCRB Issued By Chardan CapitalMarch 28, 2025 | marketbeat.comChardan Capital Reaffirms Buy Rating for Seres Therapeutics (NASDAQ:MCRB)March 21, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Price Target Cut to $0.75 by Analysts at The Goldman Sachs GroupMarch 15, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comSeres Therapeutics (MCRB) Gets a Hold from Piper SandlerMarch 14, 2025 | markets.businessinsider.comSeres Therapeutics reports FY24 EPS (81c), consensus (20c)March 13, 2025 | markets.businessinsider.comSeres Therapeutics, Inc.: Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | finanznachrichten.deSeres Therapeutics announces anticipated upcoming milestonesMarch 13, 2025 | markets.businessinsider.comSeres Therapeutics sees cash runway into 1Q26March 13, 2025 | markets.businessinsider.comSeres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comSeres Therapeutics, Inc. 2024 Q4 - Results - Earnings Call PresentationMarch 13, 2025 | seekingalpha.comSeres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | globenewswire.com Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address MCRB Media Mentions By Week MCRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MCRB News Sentiment▼1.360.65▲Average Medical News Sentiment MCRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MCRB Articles This Week▼22▲MCRB Articles Average Week Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORKA News Today SLDB News Today KURA News Today PRME News Today ARVN News Today ETON News Today SVRA News Today PVLA News Today ITOS News Today SNDL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MCRB) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access